Cross-Portfolio Strategy

Accelerating immunotherapy development – building a fast-to-market strategy.

Driven by an internal perception of a convoluted approach to clinical development, our client sought to dissect the case history of four high profile products/companies that demonstrated disproportionately speedy regulatory approval timelines.

Eradigm’s detailed appraisal of this complex scope provided extensive learnings, enabling our client to drive multiple cross-functional workstreams to rethink their approach to more dynamic decision making during development.

Testimonial about Cross-Portfolio Strategy 1